Chronic Lymphoid Leukemia Clinical Trial
Official title:
Phase III, Controlled, Double-blind, Randomized Study of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases
Recent data have shown that the inadequate vitamin D status plays a role in the manifestation
of the haematologic tumors and serum vitamin D level has a prognostic role also as it
determines the tumor mortality. But data have not proved a causal relationship between the
inadequate vitamin D status and the unfavourable outcomes so far. It is also still unknown,
whether the normalization of vitamin D status in patient with vitamin D inadequacy is able to
improve the prognosis and survival.
In this study the investigators examine the role of the adequate vitamin D substitution in
the improvement of the outcomes of haematologic disorders.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04515238 -
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL
|
Phase 2 | |
| Completed |
NCT00406809 -
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03766763 -
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A
|
Phase 2 | |
| Active, not recruiting |
NCT04608318 -
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
|
Phase 3 | |
| Active, not recruiting |
NCT04883749 -
Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL
|
Phase 2 | |
| Recruiting |
NCT03804372 -
The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide
|
Phase 2 | |
| Active, not recruiting |
NCT00788684 -
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
|
Phase 1 | |
| Completed |
NCT03787264 -
Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL
|
Phase 2 | |
| Recruiting |
NCT03852407 -
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
|
Phase 2 | |
| Recruiting |
NCT05350826 -
Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic Leukemia
|
N/A |